New drug cocktail shows promise for rare sarcoma
NCT ID NCT07548177
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether a combination of two drugs—benmelstobart (an immunotherapy) and anlotinib (a targeted therapy)—can shrink tumors in people with advanced or inoperable alveolar soft part sarcoma, a rare cancer. The study will enroll 33 participants aged 14 and older. The main goal is to see how many patients have a significant reduction in tumor size.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- benmelstobart injection and anlotinib hydrochloride capsules
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced alveolar soft part sarcoma, potentially shrinking tumors and controlling disease progression.
- What could go wrong
- This is a small, early-phase trial with only 33 participants and no comparison group, so results may not apply broadly. The drugs can cause side effects like fatigue, high blood pressure, or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALVEOLAR SOFT PART SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150081, China
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, 450000, China
-
Shandong First Medical University Affiliated Tumor Hospital
NOT_YET_RECRUITINGJinan, Shandong, 250117, China
-
Shanghai General Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200080, China
-
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITINGGuangdong, Guangdong, 510060, China
-
The First Affiliated Hospital of Army Medical University of the People's Liberation Army of China
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, 400038, China
-
The Second Affiliated Hospital, Zhejiang University School of Medicine.
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310009, China
-
The first hospital of Jilin University
NOT_YET_RECRUITINGChangchun, Jilin, 130021, China
-
Tianjin Medical University Cancer Institute & Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300060, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITINGWuhan, Hubei, 430000, China
-
West China Hospital of Sichuan University
NOT_YET_RECRUITINGChengdu, Sichuan, 610041, China
-
Xiangya Hospital of Central South University
NOT_YET_RECRUITINGChangsha, Hunan, 410008, China
-
Xinjiang Medical University Affiliated Cancer Hospital
NOT_YET_RECRUITINGÜrümqi, Xinjiang, 830000, China
-
Zhejiang Cancer Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- New combo therapy aims to shrink sarcomas
- New pill shows promise in slowing rare Cancer's growth
- New hope for rare sarcoma patients: AL3818 drug trial underway
- New combo targets sarcoma in limbs
- Engineered immune cells take on rare solid tumors in first human trial